CTLA4 and malignant mesothelioma: When patients with malignant mesothelioma were treated with ipilimumab (cytotoxic T lymphocyte-associated antigen-4, CTLA-4 inhibitor) and nivolumab (programmed death 1 blocker, PD-1 inhibitor) in combination with UV1, they recovered more rapidly, eliciting immediate immune responses [244].